Literature DB >> 10381064

Systemic lupus erythematosus and Castleman's disease.

S Suwannaroj1, S L Elkins, R W McMurray.   

Abstract

Lymphadenopathy is a common finding in systemic lupus erythematosus (SLE), yet lymphoid malignancy is rare. Typically, adenopathy associated with SLE responds to glucocorticoid therapy. We evaluated a patient with a diagnosis of SLE who had progressive lymphadenopathy despite receiving aggressive corticosteroid therapy for SLE associated thrombocytopenia. Histopathology initially revealed an aggressive plasmacytosis characteristic of Castleman's disease (CD). CD, or angiofollicular hyperplasia, is a rare lymphoproliferative neoplasm that has features overlapping many autoimmune diseases. This disorder should be considered in autoimmune diseases with unremitting or progressive adenopathy.

Entities:  

Mesh:

Year:  1999        PMID: 10381064

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Association of Macrophage Activating Syndrome with Castleman's Syndrome in Systemic Lupus Erythematosus.

Authors:  Shamsa Shariatpanahi; Shahryar Pourfarzam; Mohammadhosein Gheini
Journal:  Iran J Pathol       Date:  2016

2.  Diffuse lymphadenopathy as the presenting manifestation of systemic lupus erythematosus.

Authors:  Lanaya Williams Smith; Allan C Gelber; Michelle Petri
Journal:  J Clin Rheumatol       Date:  2013-10       Impact factor: 3.517

3.  A case of Takayasu arteritis complicated by Castleman's disease.

Authors:  Saeko Takahashi; Ikuo Kamiyama; Akitoshi Ishizaka
Journal:  Clin Rheumatol       Date:  2008-09-30       Impact factor: 2.980

Review 4.  Systemic lupus erythematosus complicated with Castleman disease: a case-based review.

Authors:  Fatma Gül Demirkan; Sümeyra Doğan; Ayşe Kalyoncu Uçar; Hafize Emine Sönmez; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2020-08-14       Impact factor: 2.631

Review 5.  New therapeutic strategies in systemic lupus erythematosus management.

Authors:  Mariele Gatto; Margherita Zen; Luca Iaccarino; Andrea Doria
Journal:  Nat Rev Rheumatol       Date:  2019-01       Impact factor: 20.543

Review 6.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

7.  Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura.

Authors:  Ruchi Sood; Harris C Taylor; Hamed Daw
Journal:  Case Rep Hematol       Date:  2013-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.